HIMS Bases Business Model On GLP-1 Exception To FDA Compounding Policy

Hims & Hers Health Inc. (HIMS), a major telehealth company, has developed a future business model grounded on a major increase in prescribing and compounding of weight-loss drugs that relies largely on a new acquisition and use of an FDA exception allowing compounding of alternative dosage forms or strengths when an approved and available drug is not suitable for a specific patient. The company revealed in an earnings call Monday (Aug. 5) that it recently signed an agreement to purchase...